Does gender influence platelet count and reactivity to P2Y12 inhibitors?
Women have higher platelet counts and a trend toward higher platelet reactivity to P2Y12 inhibitors compared to men, generating the hypothesis that sex-specific dosing strategies may be needed.
Our findings confirm that women have a larger platelet count than men, and that this is associated to a trend towards a higher platelet reactivity. HTPR is largely represented in women with a high platelet count. This generates the hypothesis that women requiring P2Y12 inhibitors could potentially benefit from larger doses of drug or should be treated with anti-platelet agents with a low rate of HTPR.
Ranucci et al. (Wed,) studied this question.